Drugs / GSK3494245
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04504435 | Sep 2020 → Jan 2024 | leishmaniasis | GlaxoSmithKline | Terminated | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GSK3494245 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04504435 ↗ |
| Known as | DDD-01305143 | ChEMBL registry synonym — accepted as the source's own label CHEMBL5095239 ↗ |
| Action | Inhibit | “a novel highly selective Leishmania kinetoplastid proteasome inhibitor” PMID 42127151 ↗ May 2026 |
| Modality | Small molecule | — CHEMBL5095239 ↗ |
| Route | Oral | “evaluating the oral administration of GSK3494245” PMID 42127151 ↗ May 2026 |